JP2023524767A5 - - Google Patents
Info
- Publication number
- JP2023524767A5 JP2023524767A5 JP2022567240A JP2022567240A JP2023524767A5 JP 2023524767 A5 JP2023524767 A5 JP 2023524767A5 JP 2022567240 A JP2022567240 A JP 2022567240A JP 2022567240 A JP2022567240 A JP 2022567240A JP 2023524767 A5 JP2023524767 A5 JP 2023524767A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- optimized nucleotide
- cov
- nucleic acid
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063021319P | 2020-05-07 | 2020-05-07 | |
| US63/021,319 | 2020-05-07 | ||
| US202063032825P | 2020-06-01 | 2020-06-01 | |
| US63/032,825 | 2020-06-01 | ||
| US202063076718P | 2020-09-10 | 2020-09-10 | |
| US202063076729P | 2020-09-10 | 2020-09-10 | |
| US63/076,718 | 2020-09-10 | ||
| US63/076,729 | 2020-09-10 | ||
| US202063088739P | 2020-10-07 | 2020-10-07 | |
| US63/088,739 | 2020-10-07 | ||
| US202163143612P | 2021-01-29 | 2021-01-29 | |
| US202163143604P | 2021-01-29 | 2021-01-29 | |
| US63/143,612 | 2021-01-29 | ||
| US63/143,604 | 2021-01-29 | ||
| US202163146807P | 2021-02-08 | 2021-02-08 | |
| US63/146,807 | 2021-02-08 | ||
| PCT/US2021/031256 WO2021226436A1 (en) | 2020-05-07 | 2021-05-07 | Optimized nucleotide sequences encoding sars-cov-2 antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524767A JP2023524767A (ja) | 2023-06-13 |
| JP2023524767A5 true JP2023524767A5 (cg-RX-API-DMAC7.html) | 2024-05-15 |
Family
ID=78468438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567240A Pending JP2023524767A (ja) | 2020-05-07 | 2021-05-07 | SARS-CoV-2抗原をコードする最適化されたヌクレオチド配列 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240342269A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4146265A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023524767A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230008801A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021269042A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3177940A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297962A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021226436A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| CA3146369A1 (en) | 2019-07-08 | 2021-01-14 | Translate Bio, Inc. | Improved mrna-loaded lipid nanoparticles and processes of making the same |
| CN118490818A (zh) | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| WO2021249011A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
| EP4205761A4 (en) * | 2020-08-27 | 2024-05-29 | Cellid Co., Ltd | NOVEL RECOMBINANT CORONAVIRUS SPIKE PROTEIN, POLYNUCLEOTIDE, VECTOR WITH POLYNUCLEOTIDE AND VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION WITH VECTOR |
| WO2022041760A1 (en) | 2020-08-31 | 2022-03-03 | Sichuan Clover Biopharmaceuticals, Inc. | Methods and compositions for purification of trimeric fusion proteins |
| WO2022099003A1 (en) * | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
| AU2022207495A1 (en) * | 2021-01-15 | 2023-08-03 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
| US20240100151A1 (en) * | 2021-01-15 | 2024-03-28 | Moderna TX, Inc. | Variant strain-based coronavirus vaccines |
| US12397051B2 (en) * | 2021-09-14 | 2025-08-26 | Globe Biotech Limited | Vaccine for use against coronavirus and variants thereof |
| EP4183409A1 (en) * | 2021-11-17 | 2023-05-24 | Charité - Universitätsmedizin Berlin | Vaccine with improved immunogenicity against mutant coronaviruses |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| WO2023094713A2 (en) * | 2021-11-29 | 2023-06-01 | BioNTech SE | Coronavirus vaccine |
| WO2023098842A1 (en) * | 2021-12-03 | 2023-06-08 | Suzhou Abogen Biosciences Co., Ltd. | NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM SARS-CoV-2 OMICRON STRAIN |
| CA3242439A1 (en) | 2021-12-17 | 2023-06-22 | Sanofi | Lyme disease rna vaccine |
| WO2023145874A1 (ja) * | 2022-01-28 | 2023-08-03 | 国立研究開発法人医薬基盤・健康・栄養研究所 | コロナウイルスに対する新規なモノクローナル抗体 |
| CN116731192A (zh) * | 2022-03-01 | 2023-09-12 | 上海泽润生物科技有限公司 | 重组刺突蛋白及其制备方法和用途 |
| CN116768988A (zh) * | 2022-03-09 | 2023-09-19 | 中生复诺健生物科技(上海)有限公司 | 编码新型冠状病毒S蛋白的mRNA疫苗 |
| CN116768987A (zh) * | 2022-03-09 | 2023-09-19 | 中生复诺健生物科技(上海)有限公司 | 编码新型冠状病毒S蛋白的mRNA疫苗 |
| CN114404584B (zh) * | 2022-04-01 | 2022-07-26 | 康希诺生物股份公司 | 一种新型冠状病毒mRNA疫苗及其制备方法和用途 |
| WO2023214082A2 (en) | 2022-05-06 | 2023-11-09 | Sanofi | Signal sequences for nucleic acid vaccines |
| DE102023002588A1 (de) * | 2022-06-26 | 2024-01-25 | BioNTech SE | Coronavirus-Impfstoff |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| JP2025536595A (ja) | 2022-11-04 | 2025-11-07 | サノフィ パスツール インコーポレイテッド | メッセンジャーrnaテール付加の方法 |
| WO2024157279A1 (en) * | 2023-01-23 | 2024-08-02 | Indian Institute Of Science | Stabilized immunogens derived from spike of coronavirus, compositions and methods thereof |
| WO2024196683A2 (en) * | 2023-03-17 | 2024-09-26 | Research Institute At Nationwide Children's Hospital | Vsv-based sars-cov-2 vaccine candidates and igy antibodies as prophylactic and therapeutic agents against sars-cov-2 and variants of concern |
| WO2024238911A1 (en) * | 2023-05-17 | 2024-11-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant murine pneumonia virus expressing severe acute respiratory syndrome coronavirus 2 (sars-cov-2) spike protein |
| WO2025106792A1 (en) * | 2023-11-15 | 2025-05-22 | La Jolla Institute For Immunology | Prefusion-stabilized sars-cov-2 spike s2 subunit as antigen for broad pan-coronavirus vaccines |
| CN117482240B (zh) * | 2024-01-03 | 2024-04-26 | 深圳大学总医院 | 一种rna疫苗递送制剂及其制备方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| CA2569664C (en) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| KR20220038506A (ko) | 2009-06-10 | 2022-03-28 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| EA022786B1 (ru) | 2009-07-31 | 2016-03-31 | Этрис Гмбх | Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков |
| SI2506857T1 (en) | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases |
| EP4074693A1 (en) | 2011-06-08 | 2022-10-19 | Translate Bio, Inc. | Cleavable lipids |
| US9512073B2 (en) | 2011-10-27 | 2016-12-06 | Massachusetts Institute Of Technology | Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof |
| BR112014024131A2 (pt) | 2012-03-29 | 2017-07-25 | Shire Human Genetic Therapies | lipídios catiônicos ionizáveis |
| EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| EA201591283A1 (ru) | 2013-03-14 | 2016-02-29 | Шир Хьюман Дженетик Терапис, Инк. | Количественная оценка эффективности кэп матричной рнк |
| AU2014340149B2 (en) * | 2013-10-22 | 2020-12-24 | Shire Human Genetic Therapies, Inc. | CNS delivery of mRNA and uses thereof |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP4729528A3 (en) | 2014-04-25 | 2026-06-24 | Translate Bio, Inc. | Methods for purification of messenger rna |
| WO2015184256A2 (en) | 2014-05-30 | 2015-12-03 | Shire Human Genetic Therapies, Inc. | Biodegradable lipids for delivery of nucleic acids |
| CA2953341C (en) | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2016004318A1 (en) | 2014-07-02 | 2016-01-07 | Shire Human Genetic Therapies, Inc. | Encapsulation of messenger rna |
| WO2016004202A1 (en) | 2014-07-02 | 2016-01-07 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
| WO2016118724A1 (en) | 2015-01-21 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| EP3247398A4 (en) | 2015-01-23 | 2018-09-26 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| RS64331B1 (sr) | 2015-06-19 | 2023-08-31 | Massachusetts Inst Technology | Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta |
| HUE067372T2 (hu) | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| HRP20220156T1 (hr) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| US12678515B2 (en) | 2015-12-30 | 2026-07-14 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| ES3030658T3 (en) | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| WO2018081318A1 (en) * | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| US20180153822A1 (en) | 2016-11-10 | 2018-06-07 | Translate Bio, Inc. | Process of Preparing mRNA-Loaded Lipid Nanoparticles |
| CN116549671A (zh) | 2016-11-10 | 2023-08-08 | 川斯勒佰尔公司 | 用于递送mrna的改进的基于ice的脂质纳米颗粒制剂 |
| IL310939B2 (en) | 2017-02-27 | 2026-01-01 | Translate Bio Inc | Large-scale production of therapeutic preparations enriched with mRNA encoding therapeutic peptides |
| IL268856B2 (en) | 2017-02-27 | 2024-09-01 | Translate Bio Inc | Methods for purification of messenger rna |
| ES2899323T3 (es) | 2017-02-27 | 2022-03-10 | Translate Bio Inc | Métodos de purificación de ARN mensajero |
| US10780183B2 (en) * | 2017-06-19 | 2020-09-22 | Translate Bio, Inc. | Messenger RNA therapy for the treatment of Friedreich's ataxia |
| AU2019271215B2 (en) | 2018-05-16 | 2024-09-12 | Translate Bio, Inc. | Ribose cationic lipids |
| CN110974950B (zh) * | 2020-03-05 | 2020-08-07 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗 |
| CN110951756B (zh) * | 2020-02-23 | 2020-08-04 | 广州恩宝生物医药科技有限公司 | 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用 |
-
2021
- 2021-05-07 AU AU2021269042A patent/AU2021269042A1/en not_active Abandoned
- 2021-05-07 EP EP21728750.7A patent/EP4146265A1/en not_active Withdrawn
- 2021-05-07 JP JP2022567240A patent/JP2023524767A/ja active Pending
- 2021-05-07 IL IL297962A patent/IL297962A/en unknown
- 2021-05-07 WO PCT/US2021/031256 patent/WO2021226436A1/en not_active Ceased
- 2021-05-07 CA CA3177940A patent/CA3177940A1/en active Pending
- 2021-05-07 US US17/923,497 patent/US20240342269A1/en active Pending
- 2021-05-07 KR KR1020227042785A patent/KR20230008801A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103668472B (zh) | 利用CRISPR/Cas9系统构建真核基因敲除文库的方法 | |
| O'Connor et al. | Host microRNA regulation of human cytomegalovirus immediate early protein translation promotes viral latency | |
| EP4306643A3 (en) | Plasmid containing a sequence encoding an mrna with a segmented poly(a) tail | |
| WO2008140621A3 (en) | Transgenic oncolytic viruses and uses thereof | |
| ZA202202242B (en) | Isolated modified vp1 capsid protein of aav5 | |
| EP3586868A3 (en) | Liver-specific nucleic acid regulatory elements and methods and use thereof | |
| JP2018046876A5 (cg-RX-API-DMAC7.html) | ||
| JP2013507935A5 (cg-RX-API-DMAC7.html) | ||
| JP2022513718A5 (cg-RX-API-DMAC7.html) | ||
| Zárate et al. | Vesicular stomatitis virus evolution during alternation between persistent infection in insect cells and acute infection in mammalian cells is dominated by the persistence phase | |
| WO2022043321A3 (en) | Variants of a family 44 xyloglucanase | |
| Subramaniam et al. | Complete genome sequence of an Ictalurid herpesvirus 1 strain isolated from blue catfish (Ictalurus furcatus) | |
| Yodmeeklin et al. | Diverse genotypes of human enteric and non-enteric adenoviruses circulating in children hospitalized with acute gastroenteritis in Thailand, from 2018 to 2021 | |
| Brachtlova et al. | Unleashing the Full Potential of Oncolytic Adenoviruses against Cancer by Applying RNA Interference: The Force Awakens | |
| AU2003255315A1 (en) | Vaccinia virus host range genes to increase the titer of avipoxviruses | |
| Kato et al. | Phosphorylation of herpes simplex virus 1 dUTPase regulates viral virulence and genome integrity by compensating for low cellular dUTPase activity in the central nervous system | |
| Wen et al. | Complete genome sequence of a giant sea perch iridovirus in Kaohsiung, Taiwan | |
| Grobler et al. | Complete genome sequence of Matlo bat lyssavirus | |
| de la Casa-Esperon | Horizontal Transfer and the Evolution of Host‐Pathogen Interactions | |
| Henriquez et al. | Genome sequence of a novel alloherpesvirus isolated from glass catfish (Kryptopterus bicirrhis) | |
| Carl et al. | Complete genome sequence of the temperate Klebsiella pneumoniae phage KPP5665-2 | |
| WO2002101067A3 (en) | Process for the preparation of d-pantothenic acid and/or salts thereof | |
| WO2022081728A3 (en) | Modified interleukin 2 (il-2) polypeptides, and methods of making and using the same | |
| Khot et al. | Viral diversity and dynamics and CRISPR-Cas-mediated immunity in a robust alkaliphilic cyanobacterial consortium | |
| KR101329348B1 (ko) | 돼지 인터페론 알파-돼지 인터페론 감마를 동시 발현하는 재조합 아데노바이러스 |